Keyword: Robert Bradway


Amgen Takes Back Bone Drugs from GSK

18.12.2015 - US biopharmaceutical group Amgen is buying back from GlaxoSmithKline (GSK) all of its remaining rights to the bone drugs Prolia (denosumab), Xgeva (denosumab) and Vectibix...


Amgen Biosimilar Push Takes Aim at Blockbusters

07.02.2013 - Amgen said it expects generic versions of biotech drugs, known as biosimilars, to be a multibillion-dollar opportunity for the company and has targeted some of the industry's...


Amgen Trims 2012 EPS Estimate, Citing R&D Tax Credit Delay

09.01.2013 - Amgen, the world's largest biotechnology company, on Tuesday lowered its outlook for 2012 earnings per share by 10 cents, citing a delay in the impact of a U.S. tax credit for...